Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
Clinical trial NCT04833894 · RECRUITING
Trial details
- NCT number
- NCT04833894
- Sponsor
- argenx
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-26
- Primary completion
- 2027-03-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.